Compare Sana Biotechnology Inc (SANA) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.05. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VEA | |
|---|---|---|
Market Cap | $947.48M | — |
Sector | Health | — |
52-Week High | $5.92 | $73.79 |
52-Week Low | $2.68 | $58.90 |
Enterprise Value | $860.73M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VEA trades at $73.46, down 0.41% on the day, with a bullish technical outlook supported by moving averages. The ETF recently hit a 52-week high of $74.04, indicating strong momentum. Institutional interest is growing, with multiple firms increasing positions in Q2 2026. VEA offers exposure to developed international markets with a low 0.03% expense ratio, making it a cost-effective diversification tool compared to broader international or emerging market ETFs.
The outlook remains positive given institutional accumulation and technical strength, though risks include currency fluctuations and global economic sensitivity. VEA's focus on developed markets provides stability versus emerging markets, but investors should monitor international economic trends that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
